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SUMMARY. The role of hepatitis B virus (HBV) genotypes in
the outcome of acute HBV infection is unclear. In this study,
we aimed to evaluate the clinical and virological features of
patients with hepatitis B-related acute liver failure (HBV-
ALF) in the US. Clinical and laboratory features of con-
secutive patients with HBV-ALF from the US ALF Study
Group were analysed. Prevalence of HBV genotypes, precore
stop (G1896A) and core promoter dual (T1762A, A1764T)
variants among patients with HBV-ALF were compared with
a cohort of 530 patients with chronic HBV infection. Thirty-
four HBV-ALF patients were studied: mean age 41 years,
56% men, 25 had detectable HBV-DNA. HBV genotypes A,
B, C and D were found in 36, 24, 8 and 32% patients,
respectively. Precore stop and core promoter dual variants
were detected in 32 and 44% of patients, respectively.
Twenty-three (68%) patients survived: 14 after liver trans-
plant, nine without transplant. Older age was the only
independent factor associated with poor outcome. Compared
with patients with chronic HBV infection, patients with ALF
were more likely to be non-Asians (88% vs 44%, P ¼ 0.005)
and to have genotype D (32% vs 10%, P < 0.01). A higher
prevalence of HBV genotype D persisted even after matching
for race and HBeAg status (32% vs 16%, P ¼ 0.007). We
concluded that HBV genotype D was more frequently found
in patients with HBV-ALF than those with chronic HBV
infection in the US. Further studies are needed to determine
if HBV genotypes play a role in the outcome of acute HBV
infection.
Keywords: chronic hepatitis B, core promoter variants, HBV
genotype, liver transplantation, precore variants.
INTRODUCTION
Acute liver failure (ALF) is a clinical syndrome characterized
by an abrupt onset of jaundice, coagulopathy and
encephalopathy in patients without pre-existing liver disease
[1]. Approximately 7–19% of all ALF cases in the UK and the
US have been attributed to acute hepatitis B infection [2–4].
Survival in patients with hepatitis B virus-related acute liver
failure (HBV-ALF), who do not undergo liver transplant, is
poor, ranging between 19 and 33% [2–7]. Survival post-
transplant is generally >80% [8,9], but lifelong immuno-
suppressive therapy is needed and donor organs may not
become available in the short interval from diagnosis to
multi-organ failure or cerebral oedema. Therefore, a greater
understanding of the clinical outcomes and prognostic
indicators of HBV-ALF is important.
Recent studies suggest that HBV genotypes and molecular
variants may be important in the outcome of acute and
chronic HBV infection [10]. Precore stop codon (G1896A)
and core promoter dual (T1762A, A1764T) variants have been
found in a higher per cent of patients with HBV-ALF than
those with acute self-limiting HBV infection in several
studies from Asia [11–13], suggesting that acute infection
with these variants might result in a more aggressive course.
However, similar studies from the US, France and South
Africa failed to confirm the association [14–17]. The reasons
for the discrepant results are unclear but may be because of
the differences in host factors, hepatitis B e antigen (HBeAg)
status at presentation and/or background prevalence of HBV
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genotypes. Hence, studies that evaluate the role of HBV
variants in HBV-ALF should take into account HBeAg status
as well as the prevalence of HBV genotypes and variants
among patients with chronic HBV infection in that country.
The aim of this study was to evaluate the clinical features,
outcome and prognostic factors in patients with HBV-ALF in
the US. We also evaluated the virological characteristics of
HBV in patients with HBV-ALF by comparing the prevalence
of HBV genotypes, precore and core promoter variants be-
tween patients with HBV-ALF and those with chronic HBV
infection in the US.
PATIENTS AND METHODS
Patients
The US Acute Liver Failure Study Group (US ALF) is a con-
sortium of 24 tertiary liver centres interested in determining
the aetiology and outcomes of ALF [3]. Consecutive patients
from the US ALF Study Group diagnosed as HBV-ALF between
January 1998 and July 2002 were included in this study. ALF
was defined as the onset of hepatic encephalopathy and co-
agulopathy within 26 weeks of first symptoms in individuals
with no previous liver disease [18]. ALF was attributed to HBV
when hepatitis B surface antigen (HBsAg) and/or IgM hepatitis
B core antibody (anti-HBc IgM) were present in the serum [19].
Five HBsAg-positive and anti-HBc IgM-negative patients with
ALF were excluded: three had documented history of acet-
aminophen overdose, one was hepatitis C virus (HCV) anti-
body, HCV-RNA and hepatitis D virus (HDV) antibody-positive
and had ALF probably because of hepatitis C and/or hepatitis D
infection, and the fifth patient had cirrhosis in the explant liver
and was considered to have acute exacerbation of chronic
hepatitis B rather than acute HBV infection [20]. Another
patient who was positive for both anti-HBc IgM and anti-HDV
was also excluded as he likely had HBV/HDV co-infection.
Demographics, clinical, laboratory and outcome data, as
well as serum samples on all patients with HBV-ALF were
retrieved from the coordinating centre at the University of
Texas Southwestern Medical Center and sent to Dr Lok’s
laboratory at the University of Michigan Medical Center for
testing and analysis. All clinical data and serum samples
were coded to protect the identity of the study subjects. The
ALF study protocol specified collection of blood samples for
research and was approved by the Institutional Review
Board of each of the participating centres. Informed consent
was obtained from the next of kin because patients had al-
tered mental status as entry criteria. The protocol of this
ancillary study was approved by the Institutional Review
Board of the University of Michigan Medical Center.
HBV testing
Day 1 sera were tested for HBV-DNA by nested polymerase
chain reaction (PCR) assays using primers to amplify the HBV
surface and precore/core promoter regions, as described
previously [19]. For patients in whom day 1 sera were not
available, the first available serum samples were analysed.
The lower limit of detection of our PCR assay was 250 copies
of HBV-DNA per millilitre [19]. Samples with no detectable
HBV-DNA were retested using twice as much DNA extract for
the first-round PCR and twice the amount of first-round PCR
products for the second-round PCR [19]. HBV genotypes,
precore stop codon (G1896A) and core promoter dual variants
(A1762T and G1764A) were determined by line-probe assay
(Inno-Lipa; Innogenetics Inc., Ghent, Belgium) as described
previously [21]. Samples with indeterminant results in the
genotyping assay were analysed (by direct sequencing at the
DNA Sequencing Core Facility at the University of Michigan
Medical Center), using the standard protocol for the Applied
Biosystems DNA sequencer 377 (Perkin Elmer Corp., Foster
City, CA, USA) with second-round PCR primers. The precore
and core promoter region from nucleotide 1742 to 1933 was
sequenced in all samples to detect additional mutations that
were not identified by the line-probe assay [19].
Comparison between patients with HBV-ALF and chronic
HBV infection
To determine if specific HBV genotypes and precore/core
promoter variants were more prevalent among patients with
ALF, virological data from patients in this study, who had
detectable HBV-DNA were compared with that obtained in
the US HBV Epidemiology Study. The latter study aimed to
determine the prevalence of HBV genotype and precore/core
promoter variants among patients with chronic HBV infec-
tion (CHB) in the US. A total of 694 patients with CHB from 17
tertiary medical centres distributed across the US were en-
rolled; eight centres participated in both the US ALF Study and
the US HBV Epidemiology Study [6,22]. Of these, 530 had
detectable HBV-DNA by PCR and their HBV genotypes and
precore/core promoter status were tested by line-probe as-
says. Comparison of virological results by line-probe assays
was initially made between patients with HBV-ALF and all
patients in the US HBV Epidemiology Study. Subsequently, a
randomly selected cohort of CHB controls, matched for HBeAg
status and race in a 3:1 ratio, were used as controls. HBeAg
status and race were chosen for matching because the pre-
valence of precore/core promoter variants was related to
HBeAg status, while HBV genotype was related to race [6,22].
Statistical analyses
Data were expressed as mean ± SEM, unless otherwise
stated and were analysed by the SPSS version 10.0 software
package (SPSS Inc., Chicago, IL, USA). Spontaneous recov-
ery was defined as survival without liver transplantation.
Overall survival was defined as survival with or without
transplantation. Poor outcome was defined as having
undergone liver transplant or death without liver transplant.
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Categorical variables were compared by chi-square test or
Fisher’s exact test and continuous variables were compared
by the Student’s t-test, as appropriate. Duration between the
onset of symptoms or jaundice and encephalopathy, alanine
aminotransferases (ALT) and aspartate aminotransferases
(AST) and alpha-fetoprotein (AFP) levels were logarithmic-
ally transformed before comparison. Results were considered
statistically significant at P < 0.05. Univariate analysis was
performed to identify factors related to spontaneous
recovery. The variables analysed include age, gender, race,
coma stage, duration between onset of symptoms or jaun-
dice and encephalopathy, bilirubin, ALT and AST level, AST/
ALT ratio, international normalized ratio (INR), AFP,
detectable HBV-DNA by PCR, status of HBsAg and HBeAg,
HBV genotype, precore stop and core promoter dual muta-
tions. Multivariate analysis was then performed by entering
significant factors from univariate analysis with P < 0.05
into forward logistic regression to identify independent
factors associated with spontaneous recovery.
RESULTS
Characteristics of patients with HBV-ALF
Over the 55-month period, 467 patients were enrolled in the
US ALF Study, of whom 34 (7.3%) were diagnosed as having
HBV-ALF. Among the 34 patients with HBV-ALF, 29 (85%)
were HBsAg positive and 27 (79%) tested anti-HBc IgM
positive. The characteristics of the patients at presentation
are shown in Table 1. The mean age of the patients was
41 ± 3 years, and 19 (56%) were men; 17 (50%) were
white, 9 (26%) African-Americans, 4 (12%) Asians and 4
(12%) Hispanics.
Twenty-five patients (74%) had detectable HBV-DNA by
PCR. HBV genotype A was the most common (36%), fol-
lowed by genotype D (32%), B (24%) and C (8%) (Table 1).
Two patients had mixed infection with genotype B and C on
line-probe assays; line-probe assay as well as direct sequen-
cing revealed that the major genotype was genotype B in
both patients. Eight patients (32%) had the precore G1896A
mutation. Eleven patients had other precore mutations, the
most common being a G to A change at nucleotide 1899
resulting in glycine to aspartate substitution at codon 29
found in seven patients, five of whom also had the G1896A
mutation. Three patients had mutation of the start codon
including one who also had the G1896A mutation. Eleven
(44%) patients had the core promoter dual variants and four
also had the precore G1896A mutation. Fourteen patients
had other core promoter mutations, the most common being
G1757A and C1799G substitutions.
Outcomes and factors associated with outcomes
Sixteen patients did not undergo liver transplant: nine had
spontaneous recovery and seven died without transplant.
Eighteen patients underwent liver transplantation, 14 were
alive at week 3 follow-up visit. Hence, the rates of sponta-
neous recovery and overall survival were nine of 34 (26%)
and 23 of 34 (68%), respectively.
Comparison of the patients with spontaneous recovery
and those with a poor outcome (transplant or death without
transplant) showed that patients with spontaneous recovery
were significantly younger (mean age 30 ± 3 vs
45 ± 3 years, P ¼ 0.007) and had a longer interval be-
tween onset of symptoms and onset of encephalopathy
(mean 16 ± 3 vs 11 ± 3 days, P ¼ 0.013) than those with
a poor outcome (Table 1). Patients with spontaneous
recovery also tended to have higher alpha-foetoprotein
(AFP) (305 ± 188 vs 38 ± 21 ng/mL, P ¼ 0.073). None of
the virological factors including detectable HBV-DNA by
PCR, HBsAg and HBeAg status, HBV genotype or precore/
core promoter variants differed between the two groups.
When age and duration between onset of symptoms and
onset of encephalopathy were analysed by forward logistic
regression, older age was the only independent predictor of
poor outcome (OR 1.60, 95% CI 1.12–2.29, P ¼ 0.011).
Eighteen (53%) patients underwent liver transplantation.
No difference in demographics or clinical parameters was
observed between those who did and did not undergo
transplantation. Fourteen of the 18 (78%) patients who
underwent liver transplantation survived. Patients who
survived after transplantation were significantly younger
(43 ± 4 vs 57 ± 3 years, P ¼ 0.025) and had higher
platelet counts (158 ± 18 · 109/L vs 87 ± 20 · 109/L,
P ¼ 0.027) than those who died post-transplant.
Among the 16 patients who did not undergo liver trans-
plantation, those who had spontaneous recovery had a
higher level of AFP (305 ± 188 vs 1 ± 0.2 ng/mL.2, P ¼
0.007) and a lower AST level (1019 ± 314 vs
4687 ± 1185 IU/L, P ¼ 0.007) than those who died with-
out transplantation.
Comparison of virological factors between patients with
ALF-HBV and chronic HBV infection
To ascertain the role of virological factors in HBV-ALF, re-
sults of HBV genotypes, precore/core promoter variants of
patients with HBV-ALF and detectable HBV-DNA (n ¼ 25)
were compared with those with chronic HBV infection from
the US HBV Epidemiology Study. Patients with HBV-ALF
were less likely to be Asians (12% vs 56%, P ¼ 0.001) and
more likely to be infected with HBV genotype D (32% vs
10%, P < 0.01) (Table 2). There was no difference in age,
gender or frequency of precore stop or core promoter dual
variants between the two groups.
Because the prevalence of HBV genotypes and precore/
core promoter variants are closely related to race and HBeAg
status, we also compared the patients with HBV-ALF with a
randomly selected cohort of patients with chronic HBV
infection matched for race and HBeAg status. Despite
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controlling for race and HBeAg status, patients with HBV-
ALF were still more likely to be infected with HBV genotype
D (32% vs 16%, P ¼ 0.007).
DISCUSSION
In this study, the rates of overall survival and spontaneous
recovery for patients with HBV-ALF were 67 and 25%
respectively. The spontaneous recovery rate in our patients
with HBV-ALF was better than those with Wilson disease
(0%) but worse than those with acute hepatitis A (65%)
[3,7]. We found that older age was the only independent
factor associated with a poor outcome. Our results were
consistent with the King’s College criteria and the Clichy
criteria, where age was an independent factor associated
with mortality, but we were unable to identify any laborat-
ory test that predicted outcome [2,6]. This may be related to
the small sample size and differences in host factors. We did
not find any relationship between virological factors and
overall survival or spontaneous recovery, suggesting that
host factors are more important than virological factors in
determining outcomes in HBV-ALF.









(n ¼ 25) P-value
Age (years) 41 ± 3 30 ± 3 45 ± 3 0.007
Male (%) 19 (56) 7 (78) 12 (48) 0.24
Race (%) 0.53
Whites 17 (50) 6 (67) 11 (44)
African-Americans 9 (26) 2 (22) 7 (28)
Asians 4 (12) 0 4 (16)
Hispanics 4 (12) 1 (11) 3 (12)








8 ± 2 11 ± 4 7 ± 3 0.65





9/29 (27) 4/8 (50) 5/21 (24) 0.21
Creatinine (mg/dL) 1.5 ± 0.2 1.1 ± 0.2 1.7 ± 0.3 0.11
Bilirubin (mg/dL) 16.8 ± 1.6 17.3 ± 2.3 16.6 ± 2.0 0.81
ALT (IU/L) 3178 ± 530 1992 ± 497 3604 ± 684 0.42
AST (IU/L) 2391 ± 414 1019 ± 314 28905 ± 613 0.18
ALT/AST ratio 2.5 ± 0.4 3.4 ± 1.2 2.2 ± 0.4 0.33
INR 4.9 ± 0.8 3.3 ± 0.6 5.5 ± 1.0 0.21
AFP (ng/L) 127 ± 68 305 ± 188 38 ± 21 0.073
HBsAg+ (%) 29 (85) 9 (100) 20 (80) 0.29
HBeAg+ (%) 15/31 (48) 5/9 (44) 10/22 (45) 0.72
Anti-HCV+ (%) 1/33 (3) 1/9 (9) 0/24 0.27
Serum HBV-DNA+ by
PCR (%)
25/30 (83) 7/8 (88) 18/22 (82) 1.00
HBV genotype (%) 0.68
A 9 (36) 2 (29) 7 (39)
B 6 (24) 1 (14) 5 (28)
C 2 (8) 1 (14) 1 (5)
D 8 (32) 3 (43) 5 (28)
Precore G1896A
variants (%)
8/25 (32) 2/7 (29) 6/18 (33) 0.61
Core promoter TA
variants (%)
11/25 (44) 3/7 (43) 8/18 (46) 0.65
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To ascertain the role of virological factors in HBV-ALF,
we compared the prevalence of HBV genotypes and pre-
core and core promoter variants between patients with
HBV-ALF and patients with chronic HBV infection. A
significantly higher percentage of patients with HBV-ALF
were infected with HBV genotype D. In our previous study
on US patients with chronic HBV infection, HBV genotype
D was more prevalent among whites and HBeAg-negative
patients [23]. In this study, patients with HBV-ALF were
significantly less likely to be Asians. This is probably
related to the high prevalence of HBV infection in Asia.
Many Asian Americans may have been exposed to HBV at
an early age, making them less likely to acquire acute
HBV infection in adult life. After correcting for the
potential confounding effects of race and HBeAg status, a
significantly higher prevalence of HBV genotype D persis-
ted suggesting that infection with HBV genotype D is more
common among patients with HBV-ALF than those with
chronic HBV infection in the US. We acknowledge that
most if not all patients with ALF likely acquired HBV
infection in the US, while 65% of the patients with CHB
were born outside the US and could have acquired HBV
infection before moving to the US [23]. Furthermore, 16
of the 24 centres in the US ALF Study Group did not
participate in the US HBV Epidemiology Study. Thus, the
two groups of patients may have different epidemiological
and virological backgrounds.
There have been very few studies comparing the clinical
outcome of acute hepatitis B patients infected with different
HBV genotypes. A cross-sectional study in Switzerland found
that HBV genotype A and D were present in 20 and 80% of
30 patients with acute hepatitis B and in 89 and 11% of 35
patients with chronic hepatitis B, respectively [24]. Another
study in Japan reported that HBV genotypes A, B and C were
found in 10, 39 and 51%, of 61 patients with acute hepatitis
B; and in 2, 12 and 86% of 533 patients with chronic
hepatitis B, respectively [25]. The difference in prevalence of
HBV genotypes between patients with acute vs chronic HBV
infection in the same country suggests that HBV genotypes
may play a role in immune response and recovery during
acute HBV infection.
Our study found a higher prevalence of precore stop (32%)
and core promoter dual variants (44%) compared with a
previous US study [14,15]. This may be related to the in-
creased sensitivity of the line-probe assay compared with
direct sequencing. It is also possible that there has been a
shift in the prevalent HBV genotypes and associated viral
variants in the US as a result of changes in immigration
patterns.
One major limitation of our study was the small sample
size, which may have caused a type II statistical error in
determining factors associated with different clinical out-
comes. Nevertheless, HBV-ALF is a rare condition and our
series is comparable in size to many other studies on this
subject and is the largest prospective US study reported to
date. Another limitation was the lack of a control group of
patients with acute self-limiting HBV infection. Inclusion of
such a control group would help determine the role of HBV
genotypes in the course of acute HBV infection and the rate
of progression to chronic infection. Unfortunately, there is
no national database or serum repository for patients with
acute self-limiting HBV infection.





(n ¼ 530) P-value
Matched CHB
patients (n ¼ 75) P-value
Age (years) 41 ± 3 43 ± 1 0.32 46 ± 2 0.20
Male (%) 13 (52) 361 (68) 0.13 53 (73) 0.096
Race (%) 0.005 0.41
Whites 14 (56) 168 (31) 45 (60)
African-Americans 6 (24) 48 (9) 18 (24)
Asians 3 (12) 296 (56) 11 (15)
Hispanics 2 (8) 9 (2) 1 (1)
Others 0 9 (2)
HBeAg+ (%) 14/25 (56) 196/509 (39) 0.12 40/75 (53) 1.00
HBV genotype 0.006 0.007
A 9 (36) 184 (35) 54 (68)
B 6 (24) 117 (22) 4 (5)
C 2 (8) 163 (31) 8 (11)
D 8 (32) 55 (10) 12 (16)
Others 0 11 (2) 0
Precore G1896A variants (%) 8 (32) 143 (27) 0.36 12 (16) 0.08
Core promoter TA variants (%) 11 (44) 235 (44) 0.57 29 (39) 0.40
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In conclusion, we found that HBV accounts for 7% of
ALF in the US. Older age was the only predictor of poor
outcome. Virological factors including HBV genotypes and
precore/core promoter variants did not affect overall sur-
vival or the rate of spontaneous recovery among patients
with HBV-ALF. However, HBV genotype D was more fre-
quently found in patients with HBV-ALF than those with
chronic HBV infection, suggesting that HBV genotype D
may be associated with an increased risk of an aggressive
course during acute infection and/or a lower risk of pro-
gression to chronic infection. Further studies are needed to
ascertain the role of HBV genotypes in the outcome of
acute HBV infection.
ACKNOWLEDGEMENTS
C.T. Wai was supported by the Singapore HMDP Fellowship.
The US ALF Study is supported by grant no. R01-DK-58369
(W.M. Lee) from the National Institutes of Health and by the
Stephen B. Tips Memorial Fund of the Northwestern Foun-
dation. A.S.F. Lok is supported in part by National Institutes
of Health contract N01-DK-9-2323 and grants U01-DK-
57577, U01-DK-62498 and R43-AI-51919.
REFERENCES
1 Lee WM. Acute liver failure. N Engl J Med 1993; 329:
1862–1872.
2 O’Grady JG, Alexander GJ, Hayllar KM, Williams R. Early
indicators of prognosis in fulminant hepatic failure. Gas-
troenterology 1989; 97: 439–445.
3 Ostapowicz G, Fontana RJ, Schiodt FV et al. Results of a
prospective study of acute liver failure at 17 tertiary care
centers in the United States. Ann Intern Med 2002; 137:
947–954.
4 Shakil AO, Kramer D, Mazariegos GV, Fung JJ, Rakela J.
Acute liver failure: clinical features, outcome analysis, and
applicability of prognostic criteria. Liver Transpl 2000; 6:
163–169.
5 Hou J, Lin Y, Waters J et al. Detection and significance of a
G1862T variant of hepatitis B virus in Chinese patients with
fulminant hepatitis. J Gen Virol 2002; 83: 2291–2298.
6 Bernuau J, Goudeau A, Poynard T et al. Multivariate ana-
lysis of prognostic factors in fulminant hepatitis B. Hepatol-
ogy 1986; 6: 648–651.
7 Schiodt FV, Davern TJ, Obaid Shakil A, McGuire B, Samuel
G, Lee WM. Viral hepatitis-related acute liver failure. Am J
Gastroenterol 2003; 98: 448–453.
8 Devarbhavi HC, Cohen AJ, Patel R, Wiesner RH, Dickson
RC, Ishitani MB. Preliminary results: outcome of liver
transplantation for hepatitis B virus varies by hepatitis B
virus genotype. Liver Transpl 2002; 8: 550–555.
9 Steinmuller T, Seehofer D, Rayes N et al. Increasing appli-
cability of liver transplantation for patients with hepatitis
B-related liver disease. Hepatology 2002; 35: 1528–1535.
10 Chu CJ, Lok ASF. Clinical significance of hepatitis B virus
genotypes. Hepatology 2002; 35: 1274–1276.
11 Omata M, Ehata T, Yokosuka O, Hosoda K, Ohto M.
Mutations in the precore region of hepatitis B virus DNA in
patients with fulminant and severe hepatitis. N Engl J Med
1991; 324: 1699–1704.
12 Kosaka Y, Takase K, Kojima M et al. Fulminant hepatitis B:
induction by hepatitis B virus mutants defective in the
precore region and incapable of encoding e antigen. Gas-
troenterology 1991; 100: 1087–1094.
13 Sato S, Suzuki K, Akahane Y et al. Hepatitis B virus strains
with mutations in the core promoter in patients with ful-
minant hepatitis. Ann Intern Med 1995; 122: 241–248.
14 Laskus T, Persing DH, Nowicki MJ, Mosley JW, Rakela J.
Nucleotide sequence analysis of the precore region in pa-
tients with fulminant hepatitis B in the United States. Gas-
troenterology 1993; 105: 1173–1178.
15 Laskus T, Rakela J, Nowicki MJ, Persing DH. Hepatitis B virus
core promoter sequence analysis in fulminant and chronic
hepatitis B. Gastroenterology 1995; 109: 1618–1623.
16 Feray C, Gigou M, Samuel D, Bernuau J, Bismuth H, Brechot
C. Low prevalence of precore mutations in hepatitis B virus
DNA in fulminant hepatitis type B in France. J Hepatol 1993;
18: 119–122.
17 Owiredu WK, Kramvis A, Kew MC. Molecular analysis of
hepatitis B virus genomes isolated from Black African
patients with fulminant hepatitis B. J Med Virol 2001; 65:
485–492.
18 O’Grady JG, Schalm SW, Williams R. Acute liver failure:
redefining the syndromes. Lancet 1993; 342: 273–275.
19 Teo EK, Ostapowicz G, Hussain M et al. Hepatitis B infection
in patients with acute liver failure in the United States.
Hepatology 2001; 33: 972–976.
20 Perrillo RP. Acute flares in chronic hepatitis B: the natural
and unnatural history of an immunologically mediated liver
disease. Gastroenterology 2001; 120: 1009–1022.
21 Wai CT, Chu CJ, Hussain M, Lok AS. HBV genotype B is
associated with better response to interferon therapy in
HBeAg(+) chronic hepatitis than genotype C. Hepatology
2002; 36: 1425–1430.
22 Chu CJ, Keeffe EB, Han SH et al. Hepatitis B virus genotypes
in the United States: results of a nationwide study. Gastro-
enterology 2003; 125: 444–451.
23 Chu CJ, Keeffe EB, Han SH et al. Prevalence of HBV precore/
core promoter variants in the United States. Hepatology
2003; 38: 619–628.
24 Mayerat C, Mantegani A, Frei C. Does hepatitis B virus
(HBV) genotype influence the clinical outcome of HBV
infection? J Viral Hepat 1999; 6: 299–304.
25 Imamura T, Yokosuka O, Tanaka M et al. Distribution of
hepatitis B viral genotypes in acute form of liver diseases
(abstract). Hepatology 2002; 36: 369A.
APPENDIX
The US Acute Liver Failure Study Group consists of: William
M. Lee (Principal Investigator), University of Texas South-
western Medical Center, Dallas, Texas; Anne Larson, Uni-
versity of Washington, Seattle, Washington; Jeffery
S. Crippin, Washington University, St. Louis, Missouri;
 2005 Blackwell Publishing Ltd, Journal of Viral Hepatitis, 12, 192–198
HBV-related acute liver failure 197
Timothy J. Davern and Nathan Bass, University of California
at San Francisco, San Francisco, California; Michael Schil-
sky, Mt. Sinai Medical Center, New York, New York; Tim-
othy M. McCashland, University of Nebraska, Omaha,
Nebraska; J. Eileen Hay, Mayo Clinic, Rochester, Minnesota;
Natalie Murray, Baylor University Medical Center, Dallas,
Texas; A. Obaid Shakil, University of Pittsburgh, Pittsburgh,
Pennsylvania; Andres T. Blei, Northwestern University,
Chicago, Illinois; Atif Zaman, Oregon Health Sciences Uni-
versity, Portland, Oregon; Steven H.B. Han, University of
California, Los Angeles, Los Angeles, California; Robert J.
Fontana, University of Michigan, Ann Arbor, Michigan;
Brendan McGuire, University of Alabama at Birmingham,
Birmingham, Alabama; Raymond Chung, Massachusetts
General Hospital, Boston, Massachusetts; Steven Lobritto
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South Carolina, Charleston, South Carolina; Santiago Mu-
noz, Albert Einstein Medical center, Philadelphia, Pennsyl-
vania; Thomas Faust, University of Pennsylvania,
Philadelphia, Pennsylvania; Todd Stravitz, Virginia Com-
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University of California, Davis Medical Center, Sacramento,
California; Raj Santayanarana, Mayo Clinic, Jacksonville,
Florida; Arun Samanta, University of Medicine and Dentistry
of New Jersey, Newark, New Jersey.
 2005 Blackwell Publishing Ltd, Journal of Viral Hepatitis, 12, 192–198
198 C.-T. Wai et al.
